Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NYSE:DNA NASDAQ:ENLV NASDAQ:TECX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$2.95+1.4%$2.94$2.56▼$7.73$565.92M0.213.47 million shs3.49 million shsDNAGinkgo Bioworks$9.70+9.5%$8.45$5.37▼$17.58$578.78M1.791.25 million shs1.20 million shsENLVEnlivex Therapeutics$0.61-0.9%$0.76$0.59▼$2.10$144.99M1.47477,574 shs309,565 shsTECXTectonic Therapeutic$30.72+0.4%$28.98$14.39▼$36.03$577.21M3.19133,517 shs95,754 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+1.37%+11.74%+1.72%-7.81%-58.97%DNAGinkgo Bioworks+9.27%+13.88%+15.28%+51.25%+5.79%ENLVEnlivex Therapeutics-0.93%-2.09%-15.67%-44.49%-49.15%TECXTectonic Therapeutic+0.42%+2.20%+5.49%-0.13%+52.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$2.95+1.4%$2.94$2.56▼$7.73$565.92M0.213.47 million shs3.49 million shsDNAGinkgo Bioworks$9.70+9.5%$8.45$5.37▼$17.58$578.78M1.791.25 million shs1.20 million shsENLVEnlivex Therapeutics$0.61-0.9%$0.76$0.59▼$2.10$144.99M1.47477,574 shs309,565 shsTECXTectonic Therapeutic$30.72+0.4%$28.98$14.39▼$36.03$577.21M3.19133,517 shs95,754 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+1.37%+11.74%+1.72%-7.81%-58.97%DNAGinkgo Bioworks+9.27%+13.88%+15.28%+51.25%+5.79%ENLVEnlivex Therapeutics-0.93%-2.09%-15.67%-44.49%-49.15%TECXTectonic Therapeutic+0.42%+2.20%+5.49%-0.13%+52.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.55Moderate Buy$15.71432.69% UpsideDNAGinkgo Bioworks 1.67Reduce$8.50-12.40% DownsideENLVEnlivex Therapeutics 2.00Hold$16.502,626.82% UpsideTECXTectonic Therapeutic 3.00Buy$79.40158.46% UpsideCurrent Analyst Ratings BreakdownLatest ENLV, DNA, TECX, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/22/2026ALTAltimmune Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.006/2/2026ALTAltimmune CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/26/2026TECXTectonic Therapeutic Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy$76.00 ➝ $81.005/18/2026ALTAltimmune HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00 ➝ $20.005/14/2026ALTAltimmune Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$14.00 ➝ $11.004/21/2026TECXTectonic Therapeutic Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026DNAGinkgo Bioworks Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/13/2026TECXTectonic Therapeutic Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$75.004/7/2026ENLVEnlivex Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $20.003/27/2026ALTAltimmune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$40K14,342.16N/AN/A$1.99 per share1.48DNAGinkgo Bioworks$170.15M3.72N/AN/A$8.74 per share1.11ENLVEnlivex TherapeuticsN/AN/AN/AN/A$8.15 per shareN/ATECXTectonic TherapeuticN/AN/AN/AN/A$13.43 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.09M-$0.93N/AN/AN/A-214,860.98%-42.57%-35.57%8/11/2026 (Estimated)DNAGinkgo Bioworks-$312.76M-$5.36N/AN/AN/A-215.41%-56.08%-26.06%8/6/2026 (Estimated)ENLVEnlivex Therapeutics$1.24B-$0.55N/AN/AN/AN/A248.08%206.39%8/24/2026 (Estimated)TECXTectonic Therapeutic-$74.15M-$4.46N/AN/AN/AN/A-32.33%-30.92%8/6/2026 (Estimated)Latest ENLV, DNA, TECX, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ALTAltimmune-$0.25-$0.18+$0.07-$0.18$0.00 millionN/A5/7/2026Q1 2026DNAGinkgo Bioworks-$1.2112-$1.39-$0.1789-$1.39$42.93 million$19.00 million5/7/2026Q1 2026TECXTectonic Therapeutic-$1.16-$1.34-$0.18-$1.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.1229.5629.56DNAGinkgo BioworksN/A5.155.15ENLVEnlivex TherapeuticsN/A193.24193.24TECXTectonic TherapeuticN/A18.5118.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%DNAGinkgo Bioworks78.63%ENLVEnlivex Therapeutics1.02%TECXTectonic Therapeutic62.63%Insider OwnershipCompanyInsider OwnershipALTAltimmune1.60%DNAGinkgo Bioworks12.69%ENLVEnlivex Therapeutics12.28%TECXTectonic Therapeutic39.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune50194.47 million191.36 millionOptionableDNAGinkgo Bioworks64065.32 million57.03 millionOptionableENLVEnlivex Therapeutics70237.38 million208.23 millionOptionableTECXTectonic Therapeutic12018.87 million11.36 millionN/AENLV, DNA, TECX, and ALT HeadlinesRecent News About These CompaniesTectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Rating of "Buy" from BrokeragesJune 18, 2026 | americanbankingnews.comTectonic Therapeutic Completes Enrollment in Key TX45 TrialJune 10, 2026 | tipranks.comTectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF PatientsJune 10, 2026 | globenewswire.comTectonic Therapeutic Inc TECXMay 31, 2026 | morningstar.comMRaymond James upgrades Tectonic Therapeutic (TECX)May 27, 2026 | msn.comTectonic Therapeutics: Currently In A Catalyst VacuumMay 19, 2026 | seekingalpha.comLifeSci Capital Sticks to Its Buy Rating for Tectonic Therapeutic (TECX)May 17, 2026 | theglobeandmail.comAnalysts Are Bullish on These Healthcare Stocks: Tectonic Therapeutic (TECX), Celldex (CLDX)May 11, 2026 | theglobeandmail.comTectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business HighlightsMay 7, 2026 | globenewswire.comTectonic Therapeutic (NASDAQ:TECX) Insider Marcella Ruddy Sells 1,065 SharesMay 7, 2026 | insidertrades.comTectonic Therapeutic Appoints Jessica Chutter to Board of DirectorsApril 23, 2026 | globenewswire.comStifel initiates coverage of Tectonic Therapeutic (TECX) with buy recommendationApril 16, 2026 | msn.comTectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2April 16, 2026 | seekingalpha.comInsider Selling: Tectonic Therapeutic (NASDAQ:TECX) Insider Sells 1,000 Shares of StockApril 4, 2026 | insidertrades.comTectonic Therapeutic, Inc. $TECX Shares Sold by Ally Bridge Group NY LLCMarch 15, 2026 | defenseworld.netDInsider Selling: Tectonic Therapeutic (NASDAQ:TECX) Insider Sells 6,262 Shares of StockMarch 10, 2026 | insidertrades.comTectonic Therapeutic Announces Leadership Transition and New ChairMarch 9, 2026 | theglobeandmail.comStocks showing market leadership: Tectonic Therapeutic earns 96 RS ratingMarch 9, 2026 | msn.comTectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference TranscriptMarch 6, 2026 | seekingalpha.comTectonic Therapeutic (NASDAQ:TECX) Insider Sells 1,649 SharesMarch 6, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026Will the SpaceX IPO Put These 5 Public Space Stocks Into a Higher Orbit?By Ryan Hasson | June 2, 2026Quantum Stocks Just Got a Lifeline—Who Benefits Most?By Nathan Reiff | May 26, 20263 ETFs For the Coming Genomics RevolutionBy Nathan Reiff | June 7, 2026ENLV, DNA, TECX, and ALT Company DescriptionsAltimmune NASDAQ:ALT$2.95 +0.04 (+1.37%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$2.97 +0.02 (+0.68%) As of 07:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Ginkgo Bioworks NYSE:DNA$9.70 +0.84 (+9.51%) Closing price 06/24/2026 03:59 PM EasternExtended Trading$9.53 -0.17 (-1.76%) As of 07:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Enlivex Therapeutics NASDAQ:ENLV$0.61 -0.01 (-0.93%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$0.63 +0.02 (+3.45%) As of 07:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Tectonic Therapeutic NASDAQ:TECX$30.72 +0.13 (+0.42%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$31.77 +1.05 (+3.43%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why KB Home Could Reward Patient Investors Later Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
